13. 多発性硬化症/視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details
臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05417269 (ClinicalTrials.gov) | April 12, 2022 | 1/6/2022 | IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS Study | A Phase I/II Dose Escalation/Adaptive Design Study to Evaluate the Safety and Efficacy of IMCY-0141 in Patients With Relapsing Remitting-Multiple Sclerosis (RR-MS) | Multiple Sclerosis, Relapsing-Remitting | Drug: IMCY-0141;Drug: Placebo;Drug: Dimethyl Fumarate | Imcyse SA | NULL | Recruiting | 18 Years | 45 Years | All | 150 | Phase 1/Phase 2 | Moldova, Republic of |